Myelofibrosis

Show Only Open Trials
1.

Phase 1/2, Open-label, Dose-escalation, Multi-ctr Study to Assess Safety, Tolerability, PK, & PD of Oral NS-018 in Patients w/ Primary Myelofibrosis, Post polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis

  • Study Status: Open to Enrollment
  • Sponsor: NS Pharma
  • Disease Status and/or Stage: Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
3.

A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms

  • Study Status: Open to Enrollment
  • Sponsor: Ely Lilly
  • Disease Status and/or Stage: Polycythemia Vera (PV), Essential Thrombocythemia (ET), or Myelofibrosis (MF)
4.

Phase II randomized controlled trial of pegylated interferon alpha-2b in early primary myelofibrosis

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Low or Intermediate Stage Primary Myelofibrosis (PMF)
5.

Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis

  • Study Status: Closed to Enrollment
  • Sponsor: Incyte Corporation
  • Disease Status and/or Stage: Primary Myelofibrosis; Post Essential Thrombocythemia-myelofibrosis; Post Polycythemia Vera-myelofibrosis

Top of page